Dr. Janine Schuurman Appointed Chairwoman of The Antibody Series 2025
- Janine Schuurman to compose agenda for the conference’s special 5th anniversary edition
- On-demand lectures now available from 2024’s edition
Porto, Portugal – 9th January 2025: The Antibody Series (TAS), a leading international conference focused on innovation and advancing the field of antibody discovery and development, is pleased to announce Dr. Janine Schuurman as Chair of the highly anticipated 5th edition. The conference will take place from September 9-12, 2025, in Porto, Portugal.
Dr. Schuurman, an esteemed expert in the antibody field, brings a wealth of experience to the role. She holds a PhD from the University of Amsterdam, joining Genmab in 2000 as one of the first scientists, with her most recent position being Senior Vice President, Head Antibody Research & Technology. She joined The Antibody Society’s Board of Directors in 2020 and currently serves as President. She is a co-inventor of many therapeutic antibodies including FDA-approved therapeutics RYBREVANT® (amivantamab) and (T)EPKINLY® (epcoritamab), and of the DuoBody®, HexaBody® and HexElect® technologies.
As TAS Chair, Dr. Schuurman will set the stage with a forward-thinking scientific agenda, bringing together leading experts from academia, biotech, and pharma to discuss the future of antibody therapeutics.
Dr. Schuurman commented: “I’m honoured to chair this important and special milestone event in September. The antibody field continues to evolve at a rapid pace, and I look forward to curating a scientific program that highlights current and future antibody innovations on the horizon.”
The Antibody Series conference is hosted by FairJourney Biologics. The annual event attracts more than 200 invited global leaders across biotech, pharmaceutical, venture capital, and academic sectors and is co-joined by over 4,000 registered participants from the scientific community online.
